At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 47 enrolled
Drug / intervention
Gemcitabine +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1/2 Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Dec 24, 2014·Updated Jul 21, 2023
In Brief
A Phase 2 clinical trial evaluating Gemcitabine, Taxotere, and 3 other interventions for Metastatic Pancreatic Adenocarcinoma. Completed, enrolled 47 participants across 1 site.
Detailed Summary
This study will be looking at whether gemcitabine, taxotere, and xeloda (GTX) in combination with cisplatin and irinotecan is effective (anti-tumor activity) and safe in patients with metastatic pancreatic cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Pancreatic Adenocarcinoma
CountriesUnited States
CollaboratorsSwim Across America
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 2014
Enrollment StartFeb 2015
Primary CompletionJun 2019
Study CompletionFeb 2020
TodayJul 2026
First PostedDec 24, 2014
Enrollment StartFeb 1, 2015
Primary CompletionJun 1, 2019
Study CompletionFeb 1, 2020
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 11.5 years ago
Interventions
Gemcitabinedrug
IV on days 4 and 11 of a 21 day cycle
Taxoteredrug
IV on days 4 and 11 of a 21 day cycle
Xelodadrug
Twice a day orally on days 1 through 14 of a 21 day cycle
Cisplatindrug
IV on days 4 and 11 of a 21 day cycle
Irinotecandrug
IV on days 4 and 11 of a 21 day cycle